PROMPT:

Write a concise summary of the following:


Secretary of Health and Human Services may delay the inclusion of a biosimilar biological product on the list of extended-monopoly drugs if the manufacturer requests a delay and it is determined that there is a high likelihood that the biosimilar product will be licensed and marketed before the selected drug's expiration date.  The manufacturer of a biosimilar biological product must submit to the Secretary of Health and Human Services (HHS) information and documents necessary for the Secretary to make determinations under this subsection, as specified by the Secretary and including, to the extent available, items described in subclause (III). After the Secretary has reviewed the request and materials submitted under subclause (I), the manufacturer shall submit any additional information and documents requested by the Secretary necessary to make determinations under this subsection. The items described in this clause are the following: (aa) The manufacturing schedule for such biosimilar biological product submitted to the Food and Drug Administration during its review of the application under such section 351(k). (bb) Disclosures (in filings by the manufacturer of such biosimilar biological product with the Securities and Exchange Commission required under section 12(b), 12(g), 13(a), or 15(d) of the Securities Exchange Act of 1934 about capital investment, revenue expectations, and actions taken by the manufacturer that are typical of the normal course of business in the year (or the 2 years, as applicable) before marketing of a biosimilar biological product) that pertain to the marketing of such biosimilar biological product, or comparable documentation that is distributed to the shareholders of privately held companies.  The Internal Revenue Code of 1986 requires that manufacturers of biosimilar biological products be treated as one manufacturer for purposes of pricing. This rule applies to partnerships, syndicates, groups, joint ventures, or other organizations


CONCISE SUMMARY:

==========

RESPONSE:

The Secretary of Health and Human Services may delay the inclusion of a biosimilar biological product on the list of extended-monopoly drugs if the manufacturer requests a delay and it is determined that there is a high likelihood that the biosimilar product will be licensed and marketed before the selected drug's expiration date. The manufacturer must submit to the Secretary of Health and Human Services information and documents necessary for the Secretary to make determinations under this subsection, as specified by the Secretary and including, to the extent available, items described in subclause (III).